Clinical Trial Update: Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Ripertamab for chronic inflammatory demyelinating polyneuropathy is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Ripertamab

Snippet

Sponsor: Zhongming Qiu | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 | Status: NOT_YET_RECRUITING